Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($50.79) price objective on AstraZeneca plc (LON:AZN) in a research report released on Wednesday, August 2nd. The firm currently has a sell rating on the biopharmaceutical company’s stock.
Other research analysts have also recently issued research reports about the company. UBS AG set a GBX 5,150 ($67.07) target price on AstraZeneca plc and gave the company a neutral rating in a research note on Thursday, April 27th. HSBC Holdings plc reiterated a reduce rating and issued a GBX 4,200 ($54.69) price target on shares of AstraZeneca plc in a report on Friday, May 5th. Shore Capital reiterated a sell rating on shares of AstraZeneca plc in a report on Wednesday, May 10th. J P Morgan Chase & Co reiterated a neutral rating on shares of AstraZeneca plc in a report on Thursday, May 11th. Finally, Berenberg Bank boosted their price target on AstraZeneca plc from GBX 5,670 ($73.84) to GBX 5,850 ($76.18) and gave the company a buy rating in a report on Wednesday, May 17th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of GBX 4,932.67 ($64.24).
Shares of AstraZeneca plc (AZN) opened at 4384.00 on Wednesday. The firm has a 50-day moving average price of GBX 4,929.68 and a 200 day moving average price of GBX 4,859.79. The stock’s market cap is GBX 55.50 billion. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00.
WARNING: “AstraZeneca plc (LON:AZN) Given a GBX 3,900 Price Target by Goldman Sachs Group, Inc. (The) Analysts” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.com-unik.info/2017/08/12/goldman-sachs-group-inc-the-analysts-give-astrazeneca-plc-lonazn-a-gbx-3900-price-target-updated.html.
The company also recently announced a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be paid a dividend of GBX 68.90 ($0.90) per share. This represents a dividend yield of 1.35%. The ex-dividend date is Thursday, August 10th.
In other news, insider Nazneen Rahman bought 39 shares of the stock in a transaction dated Thursday, July 27th. The shares were acquired at an average cost of GBX 4,370 ($56.91) per share, with a total value of £1,704.30 ($2,219.43).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
What are top analysts saying about AstraZeneca plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AstraZeneca plc and related companies.